Emerging drugs for the treatment of vitiligo
Priyanka Karagaiah(Bangalore Medical College and Research Institute), Torello Lotti(University of Florence), Stephan Grabbe(Goethe University Frankfurt), Yan Valle(Perrigo (United States)), Robert A. Schwartz(Rutgers, The State University of New Jersey), Nicola Zerbinati(University of Insubria), Mohamad Goldust(Johannes Gutenberg University Mainz), Davinder Parsad(Post Graduate Institute of Medical Education and Research), Petar Vojvodić(Klinika za Psihijatrijske Bolesti Dr Laza Lazarević), Julia Sigova(Pirogov Russian National Research Medical University)
Cited by 75
Related Papers
Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
|Journal of Clinical Oncology|2009|545
A 12-week treatment with fractional CO<sub>2</sub>laser for vulvovaginal atrophy: a pilot study
|Climacteric|2014|302
Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment
|Lasers in Medical Science|2014|265
Histological study on the effects of microablative fractional CO2 laser on atrophic vaginal tissue
|Menopause The Journal of The North American Menopause Society|2015|241
Light and energy based therapeutics for genitourinary syndrome of menopause: Consensus and controversies
|Lasers in Surgery and Medicine|2017|239